New York, New York 10032

  • Cervical Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating patients who have recurrent or metastatic cancer of the cervix.

Study summary:

OBJECTIVES: - Determine the response, time to progression, disease free survival, and overall survival of patients with recurrent and/or metastatic cancer of the cervix treated with a combination of topotecan and paclitaxel. - Determine the feasibility and toxicity of this regimen in these patients. OUTLINE: Patients receive paclitaxel IV over 3 hours on day 1 and topotecan IV over 30 minutes on days 1-5. Filgrastim (G-CSF) is administered on days 6-14. Treatment repeats every 21 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 weeks. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Histologically confirmed recurrent, persistent or metastatic cervical carcinoma (squamous or adenocarcinoma), with no potentially curative standard treatment - Measurable disease or evaluable disease PATIENT CHARACTERISTICS: Age: - 18 to physiological 60 Performance status: - ECOG 0-2 Life expectancy: - Greater than 2 months Hematopoietic: - WBC greater than 3000/mm3 - Platelet count greater than 100,000/mm3 Hepatic: - Bilirubin less than 1.5 times normal - SGOT/SGPT less than 1.5 times normal Renal: - BUN less than 1.5 times normal - Creatinine less than 1.5 times normal - Creatinine clearance greater than 50 mL/min Other: - Ineligible for other high priority national or institutional study - Not pregnant or nursing - HIV negative - No prior malignancy except nonmelanoma skin cancer - No serious medical or psychiatric illness preventing treatment or informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Greater than 4 weeks since prior chemotherapy - No greater than 2 prior chemotherapy regimens - No prior taxane or camptothecin Endocrine therapy: - No concurrent hormonal therapy except that required for nondisease related conditions (e.g., insulin for diabetes) Radiotherapy: - Greater than 4 weeks since prior radiation therapy - No concurrent radiation therapy Surgery: - Greater than 4 weeks since prior surgery



Primary Contact:

Study Chair
Amy D. Tiersten, MD
Herbert Irving Comprehensive Cancer Center

Backup Contact:


Location Contact:

New York, New York 10032
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.